NRIX - Company ID 0001549595
The table below shows Nurix Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$71.91M | -$61.09M | -$41.95M | -$48.45M | -$42.63M | $8.05M |
| Capital expenditure | $1.04M | $3.48M | $2.88M | $2.28M | $3.47M | $843.00K |
| Investing cash flow | -$123.83M | $25.53M | $35.51M | $16.07M | $40.03M | -$2.39M |
| Dividends paid | - | - | - | - |
Nurix Therapeutics, Inc. reported operating cash flow of -$249.47M for fiscal year 2025. That is down 44.5% from -$172.58M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $601.00K (FY 2019) to -$249.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $19.98M | $1.47M | $1.62M | $1.48M | $1.49M | $1.36M |